Fresenius Medical Care AG (NYSE:FMS) Receives $22.00 Consensus Target Price from Analysts

Fresenius Medical Care AG (NYSE:FMS) has received an average rating of “Hold” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $22.00.

Several analysts recently weighed in on FMS shares. StockNews.com assumed coverage on Fresenius Medical Care in a research note on Wednesday, July 3rd. They issued a “strong-buy” rating on the stock. Truist Financial reduced their price target on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, July 31st.

Institutional Investors Weigh In On Fresenius Medical Care

Several hedge funds have recently modified their holdings of FMS. Raymond James & Associates raised its position in Fresenius Medical Care by 4.0% in the fourth quarter. Raymond James & Associates now owns 28,960 shares of the company’s stock valued at $603,000 after purchasing an additional 1,125 shares during the last quarter. Cerity Partners LLC raised its holdings in Fresenius Medical Care by 6.1% in the 4th quarter. Cerity Partners LLC now owns 26,786 shares of the company’s stock valued at $558,000 after buying an additional 1,545 shares during the last quarter. GAMMA Investing LLC acquired a new stake in Fresenius Medical Care during the 4th quarter worth approximately $67,000. VisionPoint Advisory Group LLC bought a new stake in Fresenius Medical Care during the 4th quarter worth approximately $812,000. Finally, QRG Capital Management Inc. grew its holdings in Fresenius Medical Care by 44.9% during the 4th quarter. QRG Capital Management Inc. now owns 45,493 shares of the company’s stock worth $948,000 after acquiring an additional 14,100 shares during the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

Fresenius Medical Care Trading Up 1.6 %

Shares of FMS opened at $18.98 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.14 and a current ratio of 1.46. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $24.70. The firm has a market cap of $11.14 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 1.01 and a beta of 0.90. The business’s fifty day moving average is $19.51 and its 200-day moving average is $19.93.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.